Clinical Trials Logo

Filter by:
NCT ID: NCT02758288 Withdrawn - BK Virus Infection Clinical Trials

BK Virus Post-Kidney Transplant: New Practice Versus Traditional Approach

Start date: September 2015
Phase:
Study type: Observational

The investigator's aim in this study is to evaluate the impact of a new standard of care protocol for the treatment of BK viremia and nephropathy (BKVAN), which includes switching from Tacrolimus to equivalent dose of Cyclosporine in patients who have been diagnosed with BK viremia or BKVAN based on their viral load, overall graft function (estimated glomerular filtration rate), acute rejection, and rate of graft loss due to rejection or BKVAN.

NCT ID: NCT02758002 Withdrawn - Atrial Fibrillation Clinical Trials

Inhibition of Atrial Fibrillation by Elimination of Transitional Mechanisms

TRANS AF
Start date: January 28, 2016
Phase: N/A
Study type: Interventional

There is growing awareness of the importance of electrical rotors to the maintenance of atrial fibrillation (AF). Recent work in our laboratory has found that AF evolves over time, from rapid, focal activation, next to transitional rotors, and finally to stable, long duration rotors, whose locations are frequently separate from the transitional rotor sites. This project will test the hypothesis that mapping and ablation of the transitional rotors sites may prevent atrial fibrillation from progressing to sustained atrial fibrillation, and therefore increase the AF initiation threshold. The investigators will test this hypothesis during clinically-indicated electrophysiology study prior to ablation of symptomatic AF.

NCT ID: NCT02757417 Withdrawn - Ureteral Injury Clinical Trials

Intravenous Sodium Fluorescein Versus Oral Phenazopyridine for Ureteral Patency

Start date: July 2016
Phase: N/A
Study type: Interventional

To determine the safety profile of sodium fluorescein in women undergoing cystoscopy during gynecologic surgery. To determine if either oral phenazopyridine or sodium fluorescein result in shorter cystoscopy times.

NCT ID: NCT02756130 Withdrawn - Clinical trials for Recurrent Ovarian Carcinoma

Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Start date: August 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies how well birinapant and carboplatin work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back. Drugs used in chemotherapy, such as birinapant and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

NCT ID: NCT02754453 Withdrawn - Weight Loss Clinical Trials

Weight Regain Study After Bariatric Surgery-A Pilot Project

Start date: July 2013
Phase: N/A
Study type: Interventional

There are three different phases to this study: 1. Screening phase to determine if you are eligible to participate in the study. 2. Study phase, which will entail diet and activity, exercise and then finally self monitoring goals. 3. End of treatment phase where you will be asked to complete questionnaires.

NCT ID: NCT02754362 Withdrawn - Glioblastoma Clinical Trials

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

Start date: November 2016
Phase: Phase 2
Study type: Interventional

This is a phase II study to determine the immunogenicity and efficacy of a vaccine composed of tumor associated long synthetic peptides mixed with Montanide ISA-51 VG administered with polyinosinic-polycytidylic acid - poly-L-lysine carboxymethylcellulose (Poly-ICLC) and bevacizumab in adults with recurrent glioblastoma.

NCT ID: NCT02753166 Withdrawn - Trauma Clinical Trials

Dexamethasone as an Immediate Intervention

Start date: January 2017
Phase: Phase 1
Study type: Interventional

To determine if a single dose of dexamethasone (5 mg) administered in the first 12 hours following a potentially traumatic event alters a) cortisol and FKBP5 RNA the next day in the periphery measured in saliva; b) FKBP5 methylation by 1 month; c) executive functioning and emotion regulation functioning; d) psychophysiological (heart rate, respiration, skin conductance) in response cued reminders of the trauma; e) enhances the likelihood of remission of PTSD symptom severity.

NCT ID: NCT02751333 Withdrawn - Esophageal Fistula Clinical Trials

Esophageal Stent Migration With Endoscopic Suture Fixation Compared to Standard Deployment

Start date: March 2016
Phase: Phase 2
Study type: Interventional

Esophageal stents are commonly used for benign esophageal pathology, especially strictures or esophageal mucosal defects such as leaks, fistulae, or perforations. The major limiting factor to stent placement is the high migration rate of the stent. Investigators are trying to prospectively evaluate the efficacy of endostitch in preventing stent migration in benign esophageal disease in comparison with standard, fully covered self-expanding metal stents (FCSEMS) placement without fixation.

NCT ID: NCT02748174 Withdrawn - Clinical trials for Post Concussive Headache

Protective HA Factors

Start date: March 2016
Phase: N/A
Study type: Interventional

This is a naturalistic study of 100 migraineurs and 75 post concussive headache patients who will be asked to record their headaches, medications, sleep and other behaviors in a smartphone app called Curelator. The software was developed to identify possible headache triggers. We seek to determine whether there might be protective headache factors. Patients will be given audio files with relaxation therapies. We seek to understand whether this self relaxation therapy and/or traditional evidence based behavioral treatment recommended during a patient visit is protective against migraine attacks.

NCT ID: NCT02747797 Withdrawn - Advanced Cancer Clinical Trials

Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations

Start date: April 2017
Phase: Phase 2
Study type: Interventional

Lucitanib is an oral multi kinase inhibitor designed to block the action of certain molecules called "angiogenic factors" that may cause tumors to grow. These factors are called vascular endothelial growth factor (VEGF), platelet derived growth factor receptor (PDGFR) and fibroblast growth factor (FGF). Lucitanib is experimental and not approved by the FDA for the treatment of cancer. The purpose of this study is to look at the effects of lucitanib in cancer patients whose cancers harbor aberrations in FGFR, VEGFR, PDGFR or other markers predicted to be sensitive to lucitanib. This study will also look for biomarkers in samples of blood and tumor tissue to identify patients most likely to respond to lucitanib. Biomarkers are substances such as genetic material (DNA and RNA) and proteins found in blood and tumor tissue that might show if a cancer patient will respond or not respond to a drug.